within Pharmacolibrary.Drugs.ATC.A;

model A16AB03
  extends Pharmacokinetic.Models.PK_1C_enteral(
    weight         = 70,
    F              = 1,
    Cl             = 2.1 / 1000 / 60,
    adminDuration  = 600,
    adminMass      = 0.2 / 1000000,
    adminCount     = 1,
    Vd             = 0.0036,
    Cmin           = 0.001,
    Cmax           = 0.01,
    Ctox_peak      = 0.02,
    Ctox_trough    = 0.01,
    ka             = 0.016666666666666666,
    Tlag           = 600
  );

  annotation(Documentation(
    info ="<html><body><p>Agalsidase alfa is a recombinant human alpha-galactosidase A enzyme replacement therapy used to treat Fabry disease, a rare X-linked lysosomal storage disorder characterized by deficient activity of the alpha-galactosidase A enzyme. It helps to reduce the accumulation of globotriaosylceramide (GL-3) in various tissues. Agalsidase alfa is approved and in current clinical use for long-term enzyme replacement therapy in patients with Fabry disease.</p><h4>Pharmacokinetics</h4><p>Pharmacokinetic parameters reported in adult patients with Fabry disease after intravenous infusion of agalsidase alfa 0.2 mg/kg. Parameters from population pharmacokinetics and noncompartmental analyses.</p><h4>References</h4><ol><li><p>Murray, GJ, et al., &amp; Schiffmann, R (2007). Cellular and tissue distribution of intravenously administered agalsidase alfa. <i>Molecular genetics and metabolism</i> 90(3) 307–312. DOI:<a href=&quot;https://doi.org/10.1016/j.ymgme.2006.11.008&quot;>10.1016/j.ymgme.2006.11.008</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/17188539/&quot;>https://pubmed.ncbi.nlm.nih.gov/17188539</a></p></li><li><p>Clarke, JT, et al., &amp; Schiffmann, R (2007). The pharmacology of multiple regimens of agalsidase alfa enzyme replacement therapy for Fabry disease. <i>Genetics in medicine : official journal of the American College of Medical Genetics</i> 9(8) 504–509. DOI:<a href=&quot;https://doi.org/10.1097/GIM.0b013e318133fb1b&quot;>10.1097/GIM.0b013e318133fb1b</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/17700388/&quot;>https://pubmed.ncbi.nlm.nih.gov/17700388</a></p></li><li><p>Baehner, F, et al., &amp; Beck, M (2003). Enzyme replacement therapy in heterozygous females with Fabry disease: results of a phase IIIB study. <i>Journal of inherited metabolic disease</i> 26(7) 617–627. DOI:<a href=&quot;https://doi.org/10.1023/b:boli.0000005658.14563.77&quot;>10.1023/b:boli.0000005658.14563.77</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/14707510/&quot;>https://pubmed.ncbi.nlm.nih.gov/14707510</a></p></li></ol></body></html>",
    revisions = "<html><body><ul><li>06/2025 model generated by LLM gpt-4.1, references by scholarly and scripts created by Tomas Kulhanek</li></ul></body></html>"
  ));
end A16AB03;
